CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Twelve-hundred (1,200) patients admitted for 48 hours or more for COVID were randomized to 2.5mg of apixaban or placebo twice daily for 30 days. The incidence of death or thromboembolism was low and similar in the two arms of this study. The study was terminated early and the authors say the results are imprecise.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
